What is HC Wainwright’s Forecast for ALDX FY2026 Earnings?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research note issued to investors on Wednesday, March 18th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will earn ($0.44) per share for the year, down from their prior forecast of ($0.15). HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.27) EPS, FY2028 earnings at $0.09 EPS, FY2029 earnings at $0.24 EPS and FY2030 earnings at $0.21 EPS.

Separately, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ:ALDX opened at $1.83 on Friday. Aldeyra Therapeutics has a 1-year low of $1.07 and a 1-year high of $6.87. The company has a market capitalization of $110.13 million, a P/E ratio of -3.21 and a beta of 0.97. The firm’s 50 day simple moving average is $4.82 and its two-hundred day simple moving average is $5.03.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03.

Institutional Trading of Aldeyra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Inspirion Wealth Advisors LLC purchased a new position in Aldeyra Therapeutics in the 4th quarter worth approximately $52,000. Global Retirement Partners LLC purchased a new stake in Aldeyra Therapeutics during the 4th quarter valued at approximately $52,000. CIBC Private Wealth Group LLC bought a new stake in shares of Aldeyra Therapeutics during the third quarter valued at approximately $55,000. BNP Paribas Financial Markets raised its position in shares of Aldeyra Therapeutics by 36.9% during the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 2,859 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics in the fourth quarter worth $62,000. Institutional investors own 59.71% of the company’s stock.

Trending Headlines about Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Insider buy — Director/officer Michael Alfieri purchased 5,000 shares at about $1.42, increasing his stake; a small sign of insider conviction amid the selloff. SEC filing: insider purchase
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating and set a $2.00 price target (down from prior levels), signaling limited upside in analysts’ views even as they adjust forecasts. HC Wainwright reaffirms neutral
• Negative Sentiment: FDA rejection — The third CRL for reproxalap (NDA for dry eye) is the primary driver of the crash; the FDA cited insufficient efficacy, prompting the market to reprice the program’s value and near‑term revenue prospects. Zacks: FDA issues third CRL
• Negative Sentiment: Analyst cuts — HC Wainwright materially trimmed EPS forecasts across FY2026–FY2030 (Q4 2026 and multi‑year outlooks lowered), and slashed prior price expectations, reflecting weaker commercialization prospects and pushing sentiment lower. Benzinga: HC Wainwright coverage
• Negative Sentiment: Litigation risk — Multiple law firms (Pomerantz, Levi & Korsinsky, Block & Leviton, others) have launched securities‑fraud investigations and class‑action solicitations citing alleged misstatements about reproxalap’s prospects, increasing legal overhang and downside risk for shareholders. PR Newswire: Pomerantz investigation
• Negative Sentiment: Bearing bets — Elevated put‑option activity and reported heavy bearish trading suggest traders are positioning for additional downside or volatility, which can amplify moves. American Banking News: put option activity

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.